MD937C2 - Transdermal therapeutic system for cutaneous application of physostigmine on the skin and process for obtaining it - Google Patents

Transdermal therapeutic system for cutaneous application of physostigmine on the skin and process for obtaining it

Info

Publication number
MD937C2
MD937C2 MD94-0311A MD940311A MD937C2 MD 937 C2 MD937 C2 MD 937C2 MD 940311 A MD940311 A MD 940311A MD 937 C2 MD937 C2 MD 937C2
Authority
MD
Moldova
Prior art keywords
skin
therapeutic system
transdermal therapeutic
physostigmin
intermediate layer
Prior art date
Application number
MD94-0311A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD940311A (en
MD937B2 (en
Inventor
Lothar Deurer
Thomas Hille
Thomas Profitlich
Fritz Stanislaus
Kersten Walter
Original Assignee
Lts Lohmann Therapie-Systeme Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie-Systeme Gmbh & Co.Kg filed Critical Lts Lohmann Therapie-Systeme Gmbh & Co.Kg
Publication of MD940311A publication Critical patent/MD940311A/en
Publication of MD937B2 publication Critical patent/MD937B2/xx
Publication of MD937C2 publication Critical patent/MD937C2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

The invention relates to the transdermal therapeutic system (TTS) for administering physostigmin, as the active component, through the skin, as well as to the method for producing thereof.The transdermal therapeutic system for administering physostigmin through the skin consists of the impermeable to the active substance adhesive intermediate layer base containing 40...90% of polymer material and 0,1...20% of physos-tigmin base or one of its pharmaceutically acceptable salts, as well as a protective film covering the intermediate layer, and the intermediate layer contains the polymer material on the acrylate and/or methacrylate base and 0,1...40% of a plasticizer containing hydroxyl groups having an HLB value 1,1...12,0.The technical result of the invention consists in the durability and time of the TTS fixation to the skin increasing, and the physostigmin stability long-term conserving.
MD94-0311A 1992-11-12 1994-07-26 Transdermal therapeutic system for cutaneous application of physostigmine on the skin and process for obtaining it MD937C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4238223A DE4238223C1 (en) 1992-11-12 1992-11-12 Transdermal therapeutic system for the administration of physostigmine to the skin and method for its production

Publications (3)

Publication Number Publication Date
MD940311A MD940311A (en) 1998-03-31
MD937B2 MD937B2 (en) 1998-03-31
MD937C2 true MD937C2 (en) 1999-01-31

Family

ID=6472735

Family Applications (1)

Application Number Title Priority Date Filing Date
MD94-0311A MD937C2 (en) 1992-11-12 1994-07-26 Transdermal therapeutic system for cutaneous application of physostigmine on the skin and process for obtaining it

Country Status (32)

Country Link
US (1) US5698216A (en)
EP (1) EP0667774B1 (en)
JP (1) JP3407073B2 (en)
KR (1) KR100254573B1 (en)
CN (1) CN1088457A (en)
AT (1) ATE156356T1 (en)
AU (1) AU684256B2 (en)
CA (1) CA2147274C (en)
CZ (1) CZ284008B6 (en)
DE (2) DE4238223C1 (en)
DK (1) DK0667774T3 (en)
EE (1) EE03135B1 (en)
EG (1) EG20527A (en)
ES (1) ES2105334T3 (en)
FI (1) FI952269L (en)
GR (1) GR3024720T3 (en)
HR (1) HRP931391B1 (en)
HU (1) HUT72963A (en)
IL (1) IL107547A (en)
LT (1) LT3107B (en)
LV (1) LV10749B (en)
MD (1) MD937C2 (en)
MY (1) MY111373A (en)
NO (1) NO306760B1 (en)
NZ (1) NZ257136A (en)
PL (1) PL172999B1 (en)
RU (1) RU2108812C1 (en)
SI (1) SI9300589A (en)
SK (1) SK280185B6 (en)
WO (1) WO1994010999A1 (en)
YU (1) YU71293A (en)
ZA (1) ZA938413B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4446600A1 (en) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermal absorption of active ingredients from supercooled melts
DE19828273B4 (en) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing hormones and crystallization inhibitors
DE19923551A1 (en) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmaceutical preparation with the active ingredient diamorphine and its use in a method for treating opiate addiction
DE10220230A1 (en) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Use of Rotigotine to treat restless leg syndrome
AT500143A1 (en) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag CHOLINESTERASE INHIBITORS IN LIPOSOMES AND THEIR PREPARATION AND USE
ITMI20041628A1 (en) * 2004-08-06 2004-11-06 Bouty S P A THERAPEUTIC SYSTEM WITH CONTROLLED RELEASE FOR TOPICAL TRANSDERMAL USE

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3921363A (en) * 1974-05-17 1975-11-25 Preston Metal & Roofing Prod Cross member with end connector
DE3528979A1 (en) * 1984-08-14 1986-02-27 State Of Israel Represented By The Prime Minister's Office Israel Institute For Biological Research, Ness-Ziona DRUG RELEASE SYSTEM
DE3606892A1 (en) * 1985-03-05 1986-09-18 Ciba-Geigy Ag, Basel PHARMACEUTICAL FORMULATIONS AND METHOD FOR TREATING MEMORY MALFUNCTIONS
DE3843239C1 (en) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE3843238C1 (en) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
WO1991015176A1 (en) * 1990-04-06 1991-10-17 Pharmetrix Corporation Device and method for enhanced administration of physostigmine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350581A (en) * 1989-12-14 1994-09-27 Pharmetrix Corporation Method for manufacturing transdermal devices
NZ237241A (en) * 1990-03-02 1993-11-25 Pharmetrix Corp Method for increasing the storage stability of physostigmine
JP4355469B2 (en) * 2002-03-08 2009-11-04 日本碍子株式会社 Alumina-supported support, catalyst body, and method for producing alumina-supported support

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3921363A (en) * 1974-05-17 1975-11-25 Preston Metal & Roofing Prod Cross member with end connector
DE3528979A1 (en) * 1984-08-14 1986-02-27 State Of Israel Represented By The Prime Minister's Office Israel Institute For Biological Research, Ness-Ziona DRUG RELEASE SYSTEM
DE3606892A1 (en) * 1985-03-05 1986-09-18 Ciba-Geigy Ag, Basel PHARMACEUTICAL FORMULATIONS AND METHOD FOR TREATING MEMORY MALFUNCTIONS
DE3843239C1 (en) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE3843238C1 (en) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
WO1991015176A1 (en) * 1990-04-06 1991-10-17 Pharmetrix Corporation Device and method for enhanced administration of physostigmine

Also Published As

Publication number Publication date
CA2147274C (en) 2005-12-13
SK59395A3 (en) 1996-05-08
LTIP1469A (en) 1994-06-15
AU5338594A (en) 1994-06-08
CN1088457A (en) 1994-06-29
ATE156356T1 (en) 1997-08-15
HU9501390D0 (en) 1995-06-28
JPH08502986A (en) 1996-04-02
CA2147274A1 (en) 1994-05-26
YU71293A (en) 1996-07-24
IL107547A (en) 1996-12-05
SK280185B6 (en) 1999-09-10
HRP931391B1 (en) 1999-12-31
MD940311A (en) 1998-03-31
CZ284008B6 (en) 1998-07-15
ZA938413B (en) 1994-06-09
WO1994010999A1 (en) 1994-05-26
AU684256B2 (en) 1997-12-11
RU2108812C1 (en) 1998-04-20
NO951864D0 (en) 1995-05-11
KR950703948A (en) 1995-11-17
NZ257136A (en) 1996-07-26
EP0667774A1 (en) 1995-08-23
LV10749B (en) 1996-06-20
MD937B2 (en) 1998-03-31
DE59307089D1 (en) 1997-09-11
FI952269A7 (en) 1995-05-10
EP0667774B1 (en) 1997-08-06
US5698216A (en) 1997-12-16
LT3107B (en) 1994-12-27
ES2105334T3 (en) 1997-10-16
FI952269A0 (en) 1995-05-10
LV10749A (en) 1995-08-20
NO306760B1 (en) 1999-12-20
HUT72963A (en) 1996-06-28
NO951864L (en) 1995-05-11
HRP931391A2 (en) 1995-02-28
DK0667774T3 (en) 1998-03-23
JP3407073B2 (en) 2003-05-19
SI9300589A (en) 1994-06-30
EG20527A (en) 1999-06-30
IL107547A0 (en) 1994-02-27
DE4238223C1 (en) 1994-05-26
GR3024720T3 (en) 1997-12-31
MY111373A (en) 1999-12-31
EE03135B1 (en) 1998-12-15
KR100254573B1 (en) 2000-05-01
FI952269L (en) 1995-05-10
CZ124495A3 (en) 1996-01-17
PL172999B1 (en) 1998-01-30
PL308531A1 (en) 1995-08-21

Similar Documents

Publication Publication Date Title
YU47076B (en) PROCEDURE FOR DEVELOPING A TRANSDERMAL THERAPEUTIC SYSTEM WITH PHYSOSTIGMIN AS AN ACTIVE INGREDIENT
MY109926A (en) Transdermal therapeutic system comprising galanthamine as active component
YU47077B (en) PROCEDURE FOR DEVELOPING A TRANSDERMAL THERAPEUTIC SYSTEM WITH PHYSOSTIGMIN AS AN ACTIVE INGREDIENT
NO20001003D0 (en) Transdermal therapeutic system comprising a pressure sensitive adhesive reservoir layer and a unidirectional elastic cover layer
MD937C2 (en) Transdermal therapeutic system for cutaneous application of physostigmine on the skin and process for obtaining it
DE3770836D1 (en) DERMAL AND TRANSDERMAL THERAPEUTIC SYSTEMS WITH PATTERN-BASED ADHESIVE LAYER, AND METHOD FOR THE PRODUCTION THEREOF.
HUP9600147A1 (en) Transdermal therapeutic system containing molsidomine or it's metabolite and process for producing the same

Legal Events

Date Code Title Description
FG4A Patent for invention issued
IF99 Valid patent on 19990615

Free format text: EXPIRES: 20140726